Moderna

Health Canada on Moderna’s Spikevax Covid-19 vaccine

eAwaz Medicine

Ottawa – The vaccine is approved for people who are 6 years of age and older. Its safety and effectiveness in people younger than 6 years of age have not yet been established.

Effectiveness

Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax® COVID vaccine was:

  • 94.1% effective in protecting trial participants aged 18 and above against COVID-19
  • 100% effective in trial participants 12 to 17 years old
  • as effective in trial participants 6 to 11 years old as young adults (18 to 25 years old)

Dosage

The dosing schedule approved by Health Canada is to give 2 doses (100 micrograms each for ages 12 and older or 50 micrograms each for ages 6 to 11) 1 month apart, based on evidence from clinical trials.

A booster dose (50 micrograms) of the Moderna Spikevax® COVID-19 vaccine may be administered in individuals 18 years of age and older at least 6 months after completing their primary vaccine series.

Dose volume depends on which series of the vaccine is being administered. The dose for individuals 12 years of age and older (100 micrograms) is twice the dose used for children 6 to 11 years of age (50 micrograms). The booster dose is also 50 micrograms.

Check the colour of the vial cap and the corresponding dose volumes to select the appropriate dose volume for the vaccine series being administered. The 0.2 mg/mL multi-dose vial has a red plastic cap. The 0.1 mg/mL multi-dose vial has a royal blue plastic cap. The vials with royal blue caps make it easier to administer smaller doses.

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence.

Mixed dose schedules

A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty® as your first dose and be offered Moderna Spikevax® as your second. This is known as a mixed vaccine series.

The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty® or Moderna Spikevax®) should be offered for your second dose.